iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - iRhythm Technologies, Inc. reported significant growth and transformation in 2024, achieving a record number of Zio registrations and serving over 2 million patients [3] - The company secured FDA clearance for two 510(k) submissions related to its Zio AT device, enhancing its technology offerings [3] - iRhythm expanded its operations into four European countries and received regulatory approval in Japan, indicating a strategic move towards global growth [3] Operational Highlights - The company anticipates full-year 2024 revenue to exceed the high end of its previously stated guidance of $587.5 million [6] - A record number of new account openings for both Zio monitor and Zio AT were achieved in Q4 2024, alongside strong contributions from large national accounts [6] - iRhythm launched its first four healthcare systems on Epic Aura in Q4 2024, with a broader rollout planned for 2025 [6] Future Outlook - Revenue for the full year 2025 is expected to be approximately$675 million to $685 million, reflecting continued growth [6] - The company plans to enhance its quality systems and expand into primary care channels, focusing on population health management [3] - iRhythm aims to drive further penetration in international markets where it is still early in the commercial adoption curve [3]